Standout Papers

Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell... 2021 2026 2022 2024199
  1. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial (2021)
    Nasser K. Altorki, Timothy E. McGraw et al. The Lancet Oncology

Immediate Impact

5 by Nobel laureates 3 from Science/Nature 54 standout
Sub-graph 1 of 24

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
2 intermediate papers

Works of Benjamin E. Lee being referenced

Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report
2021
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Benjamin E. Lee 64 190 221 82 9 402
Niklaus Schäfer 47 121 145 30 11 341
DC Ihde 40 128 204 34 13 397
Laura Kirby 36 122 239 35 11 350
O. Lindén 62 42 143 79 13 424
Nicholas P. Schaub 30 46 215 138 8 385
Marcel H. Thelen 30 37 248 81 11 408
Karen Giselle Chee 13 161 178 33 9 371
J. Curschmann 54 170 56 26 6 424
Shotaro Kato 8 131 285 73 13 405
Lisa Blaydorn 16 68 285 88 8 381

All Works

Loading papers...

Rankless by CCL
2026